Drug industry study contradicts FTC, CBO analysis on "pay-for-delay" deals

08/12/2010 | Hill, The

Federal authorities "significantly overstated" potential savings from banning "reverse payment," or "pay-for-delay," agreements, an industry-funded study found. "Under many circumstances, reverse payment patent settlements between branded and generic manufacturers can benefit competition and consumers," according to the study.

View Full Article in:

Hill, The